Publications by authors named "B Mackert"
Background: Oral anticoagulation (OAC) is key in stroke prevention in patients with atrial fibrillation (AF) but there is uncertainty regarding the optimal timing of OAC (re)initiation after stroke, as recent large randomised controlled trials have methodological weaknesses and excluded stroke patients on therapeutic anticoagulation at stroke onset as well as patients started on a vitamin K antagonist after stroke. The '1-3-6-12 days rule', based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013.
Methods: We retrospectively assessed whether compliance to the '1-3-6-12 days rule' was associated with the composite endpoint (recurrent stroke, systemic embolism, myocardial infarction, major bleeding or all-cause death).
Introduction: Factor Xa (FXa) inhibitors are superior to vitamin K antagonists (VKAs) in terms of avoiding hemorrhagic complications. However, no robust data are available to date as to whether this also applies to the early phase after stroke. In this prospective registry study, we aimed to investigate whether anticoagulation with FXa inhibitors in the early phase after acute ischemic stroke or transient ischemic attack (TIA) is associated with a lower risk of major bleeding events compared with VKAs.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights a selection bias in stroke research due to informed consent restrictions, particularly affecting patients with communication issues.
- An "opt-out" approach was used in the Berlin-SPecific Acute Treatment in Ischemic or hAemorrhagic Stroke with Long Term Follow-up (B-SPATIAL) registry, allowing data collection without prior consent while informing patients about the study.
- Results indicated high follow-up rates, with 83.4% of participants providing functional outcome data, demonstrating the effectiveness of the opt-out strategy in capturing important information.
Aims: We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke.
Methods: The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke.
Results: At stroke onset, an off-label daily dose was prescribed in 61 (25.